Safety and Immunogenicity of ETHIORAB Rabies Vaccine
Birhanu Hurisa1, Belete Tegbaru1, Dagmar Nolkes4, Abebe Mengesha1, Gezahegn Kebede1, Sisay Kerga1, Amdemicael Adhanom1, Alemayehu Godana1, Dereje Nigussie1, Bethelehem Newayesilasie1, Gashaw Gebrewold1, Denis Bankovskiy2, Artem Metlin3 and Kelbessa Urga1*
- *Corresponding Author:
- Birhanu Hurisa
Ethiopian Health and Nutrition Research Institute
Vaccine and Diagnostic Production Directorate
P.O.Box 1242, Addis Abeba, Ethiopia
E-mail: [email protected] gov.et, [email protected]
Received date: June 26, 2013; Accepted date: July 20, 2013; Published date: July 25, 2013
Citation: Hurisa B, Tegbaru B, Nolkes D, Mengesha A, Kebede G, et al. (2013) Safety and Immunogenicity of ETHIORAB Rabies Vaccine. J Vaccines Vaccin 4:195. doi: 10.4172/2157-7560.1000195
Copyright: © 2013 Hurisa B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Worldwide rabies in dogs is the source of 99% of human infections. This makes dogs potential reservoir and transmitters to human being. Pre and post-exposure prophylaxis are means of protection against the rabies virus. The main objective of this experiment was to determine the safety and immunogenicity of Vero cell culture based rabies vaccine “ETHIORAB” manufactured by Ethiopian Health and Nutrition Research Institute, Vaccine and Diagnostic Production Directorate. The obtained vaccine was tested on mice and satisfactory safety results were observed. Random Clinical Trial (RCT) design was used for this experiment. Twelve experimental dogs from local breed were duly conditioned during a quarantine period and assigned to two groups randomly. Group I (cases) were vaccinated subcutaneously with 1 ml of ETHIORAB. Dogs in group II served as non-vaccinated controls. To evaluate the titer of the rabies virus neutralizing antibodies (VNA), sera were analyzed by Fluorescent Antibody Virus Neutralization (FAVN) test. Serum neutralizing antibody geomtric mean titers (GMT) to rabies virus was determined at days 7, 15, 21, 30, 60 and 90. Geomtric mean titers were equal to 1.55, 1.73, 2.02, 3.45, 3.57 and 3.17 IU/ml respectively. All dogs showed VNA titers higher than the 0.5 IU/ml mandated WHO recommended threshold. This study indicated ETHIORAB rabies vaccine manufactured in Ethiopia is safe and immunogenic.